[Only registered and activated users can see links. Click Here To Register...] Recent prostate cancer mouse model study published in Nature 113 has established the efficacy of combinatorial treatment of anti CTLA4 antibody and MDSC targeted therapy against both primary and metastatic cancers, emphasising the notable efficacy of targeted therapy in combination with traditional oncotherapy
